NCT00289549View on ClinicalTrials.gov

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Leukemia, Lymphocytic, Chronic
Interventions
DRUG

forodesine hydrochloride (BCX-1777)

experimental, forodesine oral dose 200 mg administered daily.

Trial Locations (1)

77030

MD Anderson Cancer Center, University of Texas, Houston

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY